Print selected from Online session10/01/2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09889227-2.str

L13 STRUCTURE UPLOADED

=> d l13
L13 HAS NO ANSWERS
L13 STR



G1 O,S

G2 Cb,Hy

G3 F,Me

G4 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l13 ful
FULL SEARCH INITIATED 15:53:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 405 TO ITERATE

100.0% PROCESSED 405 ITERATIONS 82 ANSWERS
SEARCH TIME: 00.00.01

L14 82 SEA SSS FUL L13

=> file uspatall
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.15	991.82

Print selected from Online session10/01/2003

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION

CA SUBSCRIBER PRICE 0.00 -18.23

FILE 'USPATFULL' ENTERED AT 15:53:08 ON 10 JAN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:53:08 ON 10 JAN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l14
L15 8 L14

=> d abs bib fhitstr 1-8

L15 ANSWER 1 OF 8 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:295343 USPATFULL
TI Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
IN Dumas, Jacques, Orange, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Khire, Uday, Hamden, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Robert, Sibley N., North Haven, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Renick, Joel, Milford, CT, UNITED STATES
Gunn, David E., Hamden, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
PA BAYER CORPORATION (U.S. corporation)
PI US 2002165394 A1 20021107
AI US 2001-777920 A1 20010207 (9)
RLI Continuation-in-part of Ser. No. US 2001-758548, filed on 12 Jan 2001, PENDING Continuation-in-part.of Ser. No. US 1999-425228, filed on 22 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3722
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-44-5P**
(drug candidate; prepn. of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)
RN 284461-44-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L15 ANSWER 2 OF 8 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:251820 USPATFULL
TI Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya City, CANADA
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Renick, Joel, San Diego, CA, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA (non-U.S. corporation)
PI US 2002137774 A1 20020926
AI US 2001-907970 A1 20010719 (9)
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3732
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-44-5P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-44-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L15 ANSWER 3 OF 8 USPATFULL

AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:78859 USPATFULL

TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

IN Uday, Khire, Hamden, CT, UNITED STATES
Dumas, Jacques, Orange, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Joel, Renick, Milford, CT, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES

PA BAYER CORPORATION, Pittsburgh, PA, 15205 (U.S. corporation)

PI US 2002042517 A1 20020411

AI US 2001-948915 A1 20010910 (9)

RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED

PRAI US 1999-115877P 19990113 (60)

DT Utility

FS APPLICATION

LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201

CLMN Number of Claims: 67

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3675

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **284461-44-5P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)

RN 284461-44-5 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L15 ANSWER 4 OF 8 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for usè in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:188813 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wupperal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy P., Nashnomya City, Japan
Scott, William J., Gulford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Rena, Handen, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 2001034447 A1 20011025
AI US 2001-773604 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3666
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-44-5P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-44-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L15 ANSWER 5 OF 8 USPATFULL

AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:171152 USPATFULL

TI Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors

IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jaques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., Noth Haven, CT, United States

PI US 2001027202 A1 20011004

AI US 2001-773658 A1 20010202 (9)

RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED

PRAI US 1999-115877P 19990113 (60)

DT Utility

FS APPLICATION

LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Arlington Courthouse Plaza I, Suite 1400, 2200 Clarendon Boulevard, Arlington, VA, 22201

CLMN Number of Claims: 67

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3656

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **284461-44-5P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)

RN 284461-44-5 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L15 ANSWER 6 OF 8 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:139616 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wupperal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nashnomya City, Japan
Scott, William J., Gulford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Rena, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 2001016659 A1 20010823
AI US 2001-773672 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3652
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-44-5P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-44-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L15 ANSWER 7 OF 8 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:123628 USPATFULL
TI omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 2001011136 A1 20010802
AI US 2001-773675 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Suite 1400, 2200 Clarendon Blvd., Arlington, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3646
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-44-5P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-44-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L15 ANSWER 8 OF 8 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:123627 USPATFULL
TI Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 2001011135 A1 20010802
AI US 2001-773659 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Suite 1400, Arlington Courthouse Plaza 1, Arlington, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3686
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-44-5P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-44-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	49.16	1040.98

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-18.23

FILE 'CAPLUS' ENTERED AT 15:55:34 ON 10 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 10 Jan 2003 VOL 138 ISS 3
FILE LAST UPDATED: 9 Jan 2003 (20030109/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d his

(FILE 'HOME' ENTERED AT 15:28:08 ON 10 JAN 2003)

FILE 'REGISTRY' ENTERED AT 15:32:39 ON 10 JAN 2003
L1 STRUCTURE UPLOADED
L2 32 S L1
L3 2223 S L1 FUL

```
     FILE 'USPATFULL, USPAT2' ENTERED AT 15:33:20 ON 10 JAN 2003
L4           183 S L3

     FILE 'REGISTRY' ENTERED AT 15:36:42 ON 10 JAN 2003
L5                STRUCTURE UPLOADED
L6            50 S L5
L7          1386 S L5 FUL

     FILE 'USPATFULL, USPAT2' ENTERED AT 15:37:30 ON 10 JAN 2003
L8           151 S L7

     FILE 'REGISTRY' ENTERED AT 15:40:23 ON 10 JAN 2003
L9                STRUCTURE UPLOADED
L10          195 S L9 FUL

     FILE 'USPATFULL, USPAT2' ENTERED AT 15:40:57 ON 10 JAN 2003
L11           18 S L10

     FILE 'CAPLUS' ENTERED AT 15:43:19 ON 10 JAN 2003
L12           28 S L10

     FILE 'REGISTRY' ENTERED AT 15:52:35 ON 10 JAN 2003
L13               STRUCTURE UPLOADED
L14           82 S L13 FUL

     FILE 'USPATFULL, USPAT2' ENTERED AT 15:53:08 ON 10 JAN 2003
L15            8 S L14

     FILE 'CAPLUS' ENTERED AT 15:55:34 ON 10 JAN 2003

=> s l14
L16           9 L14

=> d l16 not l15
L15 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> s l16 not l15
              9 L14
L17           0 L16 NOT L15

=> s l15 not l16
              9 L14
L18           0 L15 NOT L16

=> d abs bib fhitstr 1-9 L16

L16  ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2003 ACS
GI
```



II



III

AB Title compds. B-NHCONH-L-(M-L1)q (I) [B = (un)substituted pyridyl, quinolinyl, isoquinolinyl; L = 5 or 6 membered cyclic structure; L1 = substituted cyclic moiety having at least 5 members; M = bridging group having at least one atom; q = 1-3; with proviso that L and L1 contain 0-4 hetero atoms, e.g., N, O and S] and their pharmaceutically acceptable salts were prepd. For example, coupling of aniline II, e.g., prepd. from Et 3-hydroxybenzoate in 4-steps, with bis(trichloromethyl)carbonate followed by 3-tert-butylaniline afforded urea III. In in vitro raf kinase assays, 112-specific examples of compds. I inhibited kinase activity with IC50 values ranging from 10 nM-10 .mu.M. Compds. I are useful for the treatment of cancerous cell growth mediated by raf kinase.

AN 2002:850357 CAPLUS

DN 137:352907

TI Preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase for the treatment of tumors and/or cancerous cell growth

IN Dumas, Jacques; Riedl, Bernd; Khire, Uday; Wood, Jill E.; Robert, Sibley N.; Monahan, Mary-Katherine; Renick, Joel; Gunn, David E.; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.

PA Bayer Corporation, USA

SO U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 758,548. CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002165394	A1	20021107	US 2001-777920	20010207
	US 2002137774	A1	20020926	US 2001-907970	20010719
	WO 2002062763	A2	20020815	WO 2002-US3361	20020207
	WO 2002062763	A3	20021010		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI	US 1999-115877P	P	19990113
	US 1999-257266	B2	19990225
	US 1999-425228	B2	19991022
	US 2001-758548	A2	20010112

US 2001-777920 A 20010207
OS MARPAT 137:352907
IT **284461-44-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)
RN 284461-44-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS
AB A review. Various signaling pathways can confer the malignant phenotype to a cell. Ras signaling proteins have been found to play an important role in controlling cellular growth. Raf-1 is a protein kinase that exerts its effects downstream of Ras in the mitogen-activated protein kinase pathway and is thus likely to be crucial in the development of the malignant phenotype. BAY 43-9006 is an orally administered selective inhibitor of Raf-1 and the first compd. of its class to enter clin. trials. This article describes the early clin. data of BAY 43-9006 in patients with advanced, refractory solid tumors. To date, over 60 patients have been treated as part of four Phase I clin. trials. Dose levels have ranged from 50mg once weekly to 200mg twice-daily in continuous administration. The drug has been generally well tolerated with no dose limiting toxicity yet encountered. The more common toxicities have involved the gastrointestinal tract (diarrhea, nausea, abdominal cramping) and the skin (pruritus, rash, cheilitis). Pharmacokinetic evaluations have found BAY 43-9006 to have considerable interpatient variability. However, there seems to be an increase in Cmax and AUC values with increasing dose. There is no clear effect of food on bioavailability. Splitting the dose to twice-daily administration has shown increases in Cmax and AUC values but is also accompanied by considerable interpatient variability.
AN 2002:785444 CAPLUS
DN 137:362317
TI BAY 43-9006: Early clinical data in patients with advanced solid malignancies
AU Hotte, Sebastien J.; Hirte, Hal W.
CS Department of Medicine, Hamilton Regional Cancer Centre, McMaster University and Division of Medical Oncology, Hamilton, ON, Can.
SO Current Pharmaceutical Design (2002), 8(25), 2249-2253
CODEN: CPDEFP; ISSN: 1381-6128
PB Bentham Science Publishers
DT Journal; General Review

LA English
IT **475207-59-1**, BAY 43-9006 mono-p-tosylate
RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BAY 43-9006 for patients with advanced solid neoplasm)
RN 475207-59-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS
GI



I

AB Urea I (BAY 43-9006), a potent Raf kinase inhibitor, was prepd. in four steps from picolinic acid with an overall yield of 63%. Significant process research enabled isolation of each intermediate and target without chromatog. purifn., and overall yield increases >50% were obsd. compared to those from previous methods. This report focuses on improved synthetic strategies for prodn. of scaled quantities of I for preclin., toxicol. studies. These improvements may be useful to assemble other urea targets as potential therapeutic agents to combat cancer.

AN 2002:713341 CAPLUS

DN 137:384728

TI A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer

AU Bankston, Donald; Dumas, Jacques; Natero, Reina; Riedl, Bernd; Monahan, Mary-Katherine; Sibley, Robert

CS Pharmaceutical Division, Bayer Research Center, West Haven, CT, 06516, USA

SO Organic Process Research & Development (2002), 6(6), 777-781
CODEN: OPRDFK; ISSN: 1083-6160

PB American Chemical Society

DT Journal

LA English

IT **284461-73-0P**, BAY 43-9006
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(scalable four-step synthesis of a Raf kinase inhibitor urea BAY 43-9006 from picolinic acid)

RN 284461-73-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS

GI



II

AB Title compds., e.g., RNHCONHZOR1 [I; R = C6H4(CMe3)-3, 2-methoxy-5-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 2-methoxy-3-quinolyl, etc.; R1 = (un)substituted acylphenyl, -acylpyridinyl, etc.; Z = (un)substituted 1,3- or -1,4-phenylene] were prepd. Thus, 4-(H2N)C6H4OC6H4(CONHMe)-4 (prepn. given) was condensed with 3-(Me3C)C6H4NH2 and CO(OCCl3)2 to give title compd. II. Data for biol. activity of title compds. were given.

AN 2002:615574 CAPLUS

DN 137:169425

TI Preparation of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors

IN Dumas, Jacques; Riedl, Bernd; Khire, Uday; Wood, Jill E.; Sibley, Robert N.; Monahan, Mary-Katherine; Renick, Joel; Gunn, David E.; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.

PA Bayer Corporation, USA

SO PCT Int. Appl., 125 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062763	A2	20020815	WO 2002-US3361	20020207
	WO 2002062763	A3	20021010		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002165394	A1	20021107	US 2001-777920	20010207
PRAI	US 2001-777920	A	20010207		
	US 1999-115877P	P	19990113		
	US 1999-257266	B2	19990225		
	US 1999-425228	B2	19991022		
	US 2001-758548	A2	20010112		

OS MARPAT 137:169425

IT **284461-44-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors)

RN 284461-44-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS
GI



II

AB This invention relates to the prepn. and use of (hetero)aryl ureas ANHCONHB [I; A = L(ML1)q; L = 5- or 6-membered (hetero)aryl, esp. Ph or pyridinyl; M = bridging group; L1 = (hetero)aryl with at least one (un)substituted sulfamoyl, carboxy, or carbamoyl substituent; q = 1-3; B = certain (un)substituted mono- to tricyclic aryl or heteroaryl groups] for the treatment of raf mediated diseases, such as cancer (no data). Approx. 100 invention compds. and numerous intermediates were prepd. For instance, 3-tert-butylaniline was coupled with bis(trichloromethyl)carbonate to form the isocyanate, followed by addn. of 4-(3-N-methylcarbamoylphenoxy)aniline (prepn. given) to afford the urea II.

AN 2000:493516 CAPLUS

DN 133:120157

TI Preparation of .omega.-carboxy(hetero)aryl substituted diphenyl ureas as raf kinase inhibitors

IN Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.

PA Bayer Corporation, USA

SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000042012	A1	20000720	WO 2000-US648	20000112

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1140840	A1	20011010	EP 2000-903239	20000112	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
US 2001011135	A1	20010802	US 2001-773659	20010202	
US 2001011136	A1	20010802	US 2001-773675	20010202	
US 2001016659	A1	20010823	US 2001-773672	20010202	
US 2001027202	A1	20011004	US 2001-773658	20010202	
US 2001034447	A1	20011025	US 2001-773604	20010202	
NO 2001003463	A	20010912	NO 2001-3463	20010712	
US 2002137774	A1	20020926	US 2001-907970	20010719	
US 2002042517	A1	20020411	US 2001-948915	20010910	
PRAI US 1999-115877P	P	19990113			
US 1999-257266	A2	19990225			
US 1999-425228	A2	19991022			
WO 2000-US648	W	20000112			

OS MARPAT 133:120157

IT **284461-44-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)

RN 284461-44-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS

GI



II

AB The title compds. ADB [I; D = NHCONH; A = substituted moiety of up to 40 carbon atoms of the formula L(ML1)q (wherein L = 5-6 membered cyclic structure; L1 = substituted cyclic moiety having at least 5 members; M = bridging group having al least one atom; q = 1-3; each of L and L1 contains 0-4 members of the group consisting of N, O and S); B = (un)substituted up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D contg. 0-4 members of the group consisting of N, O and S], useful in treating p38 mediated diseases, were prepd. E.g., a multi-step synthesis of the urea II which showed IC50 of 1-10 .mu.M against p38, was given. Compds. I are effective at 0.01-200 mg/kg/day (oral administration).

AN 2000:493376 CAPLUS

DN 133:120155

TI Preparation of .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors

IN Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.

PA Bayer Corporation, USA

SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000041698	A1	20000720	WO 2000-US768	20000113
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1158985	A1	20011205	EP 2000-905597	20000113
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1999-115878P	P	19990113		
	US 1999-257265	A2	19990225		
	US 1999-425229	A2	19991022		
	WO 2000-US768	W	20000113		

OS MARPAT 133:120155

IT **284461-86-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of .omega.-carboxy aryl substituted di-Ph ureas as p38 kinase inhibitors)

RN 284461-86-5 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS

AB A method of treating a p-38 mediated disease other than cancer comprises administration of BNHCONHA [A = (substituted) Ph, pyridyl, 2-thienyl; B = (substituted) aryl, heteroaryl contg. .gtoreq.1 6-membered arom. structure contg. 0-4 N, O, or S atoms]. Thus, 5-tert-butyl-2-(3-tetrahydrofuranyloxy)aniline (prepn. given) and p-tolyl isocyanate were stirred 8 h in PhMe to give 75% N-(5-tert-butyl-2-(3-tetrahydrofuranyloxy)phenyl)-N'-(4-methylphenyl)urea. Title compds. inhibited p38 kinase with IC50 = 1-10 .mu.M.

AN 1999:421667 CAPLUS

DN 131:58659

TI Preparation of diaryl ureas as inhibitors of p38 kinase.

IN Miller, Scott; Osterhout, Martin; Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Gunn, David; Hatoum-Mokdad, Holia; Rodriguez, Mareli; Sibley, Robert; Wang, Ming

PA Bayer Corporation, USA

SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932463	A1	19990701	WO 1998-US27265	19981222
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2315715	AA	19990701	CA 1998-2315715	19981222
	AU 9919399	A1	19990712	AU 1999-19399	19981222
	EP 1042305	A1	20001011	EP 1998-964221	19981222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001526276	T2	20011218	JP 2000-525400	19981222
PRAI	US 1997-995749	A	19971222		
	WO 1998-US27265	W	19981222		

OS MARPAT 131:58659

IT **228399-44-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of diaryl ureas as inhibitors of p38 kinase)

RN 228399-44-8 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-(3-thienyl)phenyl]-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS
GI



II

AB The invention relates to the use of a group of aryl ureas ANHCONHB [I; A = certain (un)substituted Ph, pyridinyl, or thien-2-yl groups; B = certain (un)substituted mono- to tricyclic aryl or heteroaryl groups] in treating raf-mediated diseases, and pharmaceutical compns. for use in such therapy. A subset of I are novel and are claimed per se. Approx. 160 invention compds. and numerous intermediates were prepd. For instance, reaction of tolyl isocyanate with 2-methoxy-5-(trifluoromethanesulfonyl)aniline in EtOAc gave title compd. II. In an in vitro raf kinase assay, all compds. displayed IC50 values between 1 nM and 10 .mu.M.
AN 1999:421642 CAPLUS
DN 131:58658
TI Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
IN Miller, Scott; Osterhout, Martin; Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Gunn, David; Rodriguez, Mareli; Wang, Ming
PA Bayer Corporation, USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932436	A1	19990701	WO 1998-US26081	19981222
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2315646	AA	19990701	CA 1998-2315646	19981222
	AU 9919054	A1	19990712	AU 1999-19054	19981222
	EP 1049664	A1	20001108	EP 1998-963809	19981222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001526258	T2	20011218	JP 2000-525373	19981222
	BR 9814375	A	20020521	BR 1998-14375	19981222
	NO 2000003230	A	20000821	NO 2000-3230	20000621
PRAI	US 1997-996344	A	19971222		
	WO 1998-US26081	W	19981222		

OS MARPAT 131:58658

IT **228399-40-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sym. and unsym. substituted di-Ph ureas with inhibitory effects on tumors mediated by raf kinase)

RN 228399-40-4 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[3-methyl-4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS

AB Anilines RZC6H4NH2 (R = heteroaryl, e.g., 6-chloro-3-pyridazinyl, Z = O, SO2) were prepd. and converted into their corresponding ureas, carbamates, carboxamides, and benzenesulfonamides by treatment with isocyanates, chloroformates, and acyl halides, resp.

AN 1984:510849 CAPLUS

DN 101:110849

TI Synthesis of potential plant protective agents and pesticides from substituted anilines

AU Kempter, Gerhard; Beerbalk, H. D.

CS Sekt. Chem./Biol., Paedagog. Hochsch. "Karl Liebknecht", Potsdam-Sanssouci, DDR-1500, Ger. Dem. Rep.

Print selected from Online session10/01/2003

SO Wissenschaftliche Zeitschrift der Paedagogischen Hochschule Karl Liebknecht Potsdam (1983), 27(1), 101-20
CODEN: WPKLAO; ISSN: 0138-290X
DT Journal
LA German
OS CASREACT 101:110849
IT **91619-55-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 91619-55-5 CAPLUS
CN Urea, N-[4-(3-pyridinyloxy)phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



=> file registry
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	44.99	1085.97

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.86	-24.09

FILE 'REGISTRY' ENTERED AT 16:01:33 ON 10 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JAN 2003 HIGHEST RN 478613-03-5
DICTIONARY FILE UPDATES: 9 JAN 2003 HIGHEST RN 478613-03-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09889227-2.str

L19 STRUCTURE UPLOADED

```
=> d l19
L19 HAS NO ANSWERS
L19             STR
```



G1 O,S

G2 Cb,Hy

G3 F,Me

G4 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l19 ful
FULL SEARCH INITIATED 16:03:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    327 TO ITERATE

100.0% PROCESSED     327 ITERATIONS                              82 ANSWERS
SEARCH TIME: 00.00.01

L20          82 SEA SSS FUL L19

=> d his

     (FILE 'HOME' ENTERED AT 15:28:08 ON 10 JAN 2003)

     FILE 'REGISTRY' ENTERED AT 15:32:39 ON 10 JAN 2003
L1               STRUCTURE UPLOADED
L2             32 S L1
L3           2223 S L1 FUL

     FILE 'USPATFULL, USPAT2' ENTERED AT 15:33:20 ON 10 JAN 2003
L4            183 S L3

     FILE 'REGISTRY' ENTERED AT 15:36:42 ON 10 JAN 2003
L5               STRUCTURE UPLOADED
L6             50 S L5
L7           1386 S L5 FUL

     FILE 'USPATFULL, USPAT2' ENTERED AT 15:37:30 ON 10 JAN 2003
L8            151 S L7
```

```
     FILE 'REGISTRY' ENTERED AT 15:40:23 ON 10 JAN 2003
L9              STRUCTURE UPLOADED
L10          195 S L9 FUL

     FILE 'USPATFULL, USPAT2' ENTERED AT 15:40:57 ON 10 JAN 2003
L11           18 S L10

     FILE 'CAPLUS' ENTERED AT 15:43:19 ON 10 JAN 2003
L12           28 S L10

     FILE 'REGISTRY' ENTERED AT 15:52:35 ON 10 JAN 2003
L13             STRUCTURE UPLOADED
L14           82 S L13 FUL

     FILE 'USPATFULL, USPAT2' ENTERED AT 15:53:08 ON 10 JAN 2003
L15            8 S L14

     FILE 'CAPLUS' ENTERED AT 15:55:34 ON 10 JAN 2003
L16            9 S L14
L17            0 S L16 NOT L15
L18            0 S L15 NOT L16

     FILE 'REGISTRY' ENTERED AT 16:01:33 ON 10 JAN 2003
L19             STRUCTURE UPLOADED
L20           82 S L19 FUL
```

L16 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS
GI



II

AB The invention relates to the use of a group of aryl ureas ANHCONHB [I; A = certain (un)substituted Ph, pyridinyl, or thien-2-yl groups; B = certain (un)substituted mono- to tricyclic aryl or heteroaryl groups] in treating raf-mediated diseases, and pharmaceutical compns. for use in such therapy. A subset of I are novel and are claimed per se. Approx. 160 invention compds. and numerous intermediates were prepd. For instance, reaction of tolyl isocyanate with 2-methoxy-5-(trifluoromethanesulfonyl)aniline in EtOAc gave title compd. II. In an in vitro raf kinase assay, all compds. displayed IC50 values between 1 nM and 10 .mu.M.

AN 1999:421642 CAPLUS

DN 131:58658

TI Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas

IN Miller, Scott; Osterhout, Martin; Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Gunn, David; Rodriguez, Mareli; Wang, Ming

PA Bayer Corporation, USA

SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932436	A1	19990701	WO 1998-US26081	19981222
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2315646	AA	19990701	CA 1998-2315646	19981222
	AU 9919054	A1	19990712	AU 1999-19054	19981222
	EP 1049664	A1	20001108	EP 1998-963809	19981222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001526258	T2	20011218	JP 2000-525373	19981222
	BR 9814375	A	20020521	BR 1998-14375	19981222

	NO 2000003230	A	20000821	NO 2000-3230	20000621
PRAI	US 1997-996344	A	19971222		
	WO 1998-US26081	W	19981222		

OS MARPAT 131:58658

IT **228399-40-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sym. and unsym. substituted di-Ph ureas with inhibitory effects on tumors mediated by raf kinase)

RN 228399-40-4 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[3-methyl-4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)

Print selected from Online session10/01/2003



G1 O,S

G2 Cb,Hy

G3 F,Me

Structure attributes must be viewed using STN Express query preparation.

=> s l9 ful
FULL SEARCH INITIATED 15:40:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 699 TO ITERATE

100.0% PROCESSED 699 ITERATIONS 195 ANSWERS
SEARCH TIME: 00.00.01

L10 195 SEA SSS FUL L9

=> file uspatall

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.15	604.46

FILE 'USPATFULL' ENTERED AT 15:40:57 ON 10 JAN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:40:57 ON 10 JAN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l10
L11 18 L10

=> d abs bib fhitstr 1-18

L11 ANSWER 1 OF 18 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:295343 USPATFULL
TI Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
IN Dumas, Jacques, Orange, CT, UNITED STATES

Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Khire, Uday, Hamden, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Robert, Sibley N., North Haven, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Renick, Joel, Milford, CT, UNITED STATES
Gunn, David E., Hamden, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
PA BAYER CORPORATION (U.S. corporation)
PI US 2002165394 A1 20021107
AI US 2001-777920 A1 20010207 (9)
RLI Continuation-in-part of Ser. No. US 2001-758548, filed on 12 Jan 2001, PENDING Continuation-in-part of Ser. No. US 1999-425228, filed on 22 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3722
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **228418-48-2P**
(drug candidate; prepn. of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)
RN 228418-48-2 USPATFULL
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L11 ANSWER 2 OF 18 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:251820 USPATFULL
TI Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES

Lowinger, Timothy B., Nishinomiya City, CANADA
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Renick, Joel, San Diego, CA, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA (non-U.S. corporation)
PI US 2002137774 A1 20020926
AI US 2001-907970 A1 20010719 (9)
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3732
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-33-2P**, N-(3-tert-Butylphenyl)-N'-(4-(3-(N-methylcarbamoyl)phenoxy)phenyl)urea
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-33-2 USPATFULL
CN Benzamide, 3-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L11 ANSWER 3 OF 18 USPATFULL
AB The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins. In the compounds of this invention, at least two carbo- or heterocyclic groups are attached to a central saturated, partially saturated, or aromatic 5-6 membered carbocyclic ring by a combination of straight or branched linker chains. The invention further relates to pharmaceutical compositions comprising one or more of the said compounds, and to the uses of these compounds and compositions for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity, and for research, development, and therapeutic applications in a variety of medical disorders, such as neurological disorders, hair loss disorders, ischemic disorders, and disorders caused by viral or protozoan infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:235416 USPATFULL
TI Bisubstituted carbocyclic cyclophilin binding compounds and their use

IN Hamilton, Gregory S., Catonsville, MD, UNITED STATES
Belyakov, Sergei, Baltimore, MD, UNITED STATES
Vaal, Mark, Baltimore, MD, UNITED STATES
Wei, Ling, Lutherville, MD, UNITED STATES
Wu, Yong-Qian, Columbia, MD, UNITED STATES
Steiner, Joseph P., Mt. Airy, MD, UNITED STATES
PI US 2002127605 A1 20020912
AI US 2001-994927 A1 20011128 (9)
PRAI US 2000-253074P 20001128 (60)
US 2001-291966P 20010521 (60)
DT Utility
FS APPLICATION
LREP Michael J. Bell, HOWREY SIMON ARNOLD & WHITE, LLP, Box No. 34, 1299 Pennsylvania Avenue, N.W., Washington, DC, 20004-2402
CLMN Number of Claims: 84
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3481
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **1995-43-3P**
(drug; prepn. of 1,3-disubstituted sulfonamido/amido/ureido-Ph-amides as immunophilin ligands)
RN 1995-43-3 USPATFULL
CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-(3-phenoxyphenyl)- (9CI) (CA INDEX NAME)



L11 ANSWER 4 OF 18 USPATFULL
AB The invention relates to 1,3-disubstituted ureas of general formula (I) where R.sup.1 is an aryl, R.sup.2 is nitro and/or amino, and X is oxygen and/or sulfur, and the method of preparing thereof which consists in treating aromatic amines with isocyanates. Isocyanates may be formed in situ and the reaction carried out in toluene, at 80.degree. C. If the nitro group is formed, it is reduced with hydrogen in the presence of palladium catalyst to the amino group. The obtained 1,3-disubstituted ureas are inhibitors of the activity of the acyl co-enzyme A: cholesterol acyltransferase (ACAT) enzyme, and may be used to inhibit cholesterol esterification and absorption in hypercholesterolemia. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:224626 USPATFULL
TI 1,3-disubstituted ureas as ACAT inhibitors, and method of preparing thereof
IN Oremus, Vladi{acute over (m)}ir, Bratislava, SLOVAKIA
{haeck over (S)}mahovsky , Vendelin, Pezinok, SLOVAKIA
Faberova , Viera, Bratislava, SLOVAKIA
Kakalik, Ivan, {haeck over (S)}enkvice, SLOVAKIA
Schmidtova , {haeck over (L)}udmila, Modra, SLOVAKIA

Zemanek, Marian, Bratislava, SLOVAKIA
PA Solvakofarma, a.s., Hlohovec, SLOVAKIA (non-U.S. corporation)
PI US 6444691 B1 20020903
WO 9932437 19990701
AI US 2000-581821 20000710 (9)
WO 1998-SK19 19981216
20000710 PCT 371 date
PRAI SK 1997-175197 19971219
DT Utility
FS GRANTED
EXNAM Primary Examiner: O'Sullivan, Peter
LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 683
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **228544-40-9P**
(prepn. of 1,3-disubstituted ureas as ACAT inhibitors)
RN 228544-40-9 USPATFULL
CN Urea, N-[4-(4-nitrophenoxy)phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



L11 ANSWER 5 OF 18 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:78859 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Uday, Khire, Hamden, CT, UNITED STATES
Dumas, Jacques, Orange, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Joel, Renick, Milford, CT, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA, 15205 (U.S. corporation)
PI US 2002042517 A1 20020411
AI US 2001-948915 A1 20010910 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, ABANDONED
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED

PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-33-2P**, N-(3-tert-Butylphenyl)-N'-(4-(3-(N-methylcarbamoyl)phenoxy)phenyl)urea
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-33-2 USPATFULL
CN Benzamide, 3-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L11 ANSWER 6 OF 18 USPATFULL
AB Chemical structures have been identified which allosterically modify pyrvate kinase and inhibit enzymatic activity. These compounds can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, such as the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate related to the delivery of oxygen by modifying hemoglobin's oxygen affinity, treatments of tumor and cancer and Alzheimer's disease (AD).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:218507 USPATFULL
TI Allosteric inhibitors of pyruvate kinase
IN Abraham, Donald J., Midlothian, VA, United States
Wang, Changging, Richmond, CA, United States
Danso-Danquah, Richmond, Richmond, VA, United States
Burnett, James C., Ashland, VA, United States
Joshi, Gajanan S., Glen Allen, VA, United States
Hoffman, Steven J., Carlisle, MA, United States
PI US 2001046997 A1 20011129
AI US 2001-799873 A1 20010307 (9)
RLI Continuation-in-part of Ser. No. US 1998-46643, filed on 24 Mar 1998, GRANTED, Pat. No. US 6214879
DT Utility
FS APPLICATION
LREP McGuire Woods, LLP, Suite 1800, 1750 Tysons Boulevard, Tysons Corner, McLean, VA, 22102
CLMN Number of Claims: 24
ECL Exemplary Claim: 1

Print selected from Online session10/01/2003

DRWN 7 Drawing Page(s)
LN.CNT 688
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **289060-07-7**
(pyruvate kinase allosteric inhibitors for therapeutic use)
RN 289060-07-7 USPATFULL
CN 1,3-Benzenedicarboxylic acid, 5-[4-(methoxycarbonyl)-2-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, dimethyl ester (9CI) (CA INDEX NAME)



L11 ANSWER 7 OF 18 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:188813 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wupperal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy P., Nashnomya City, Japan
Scott, William J., Gulford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Rena, Handen, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 2001034447 A1 20011025
AI US 2001-773604 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings

LN.CNT 3666
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-33-2P**, N-(3-tert-Butylphenyl)-N'-(4-(3-(N-methylcarbamoyl)phenoxy)phenyl)urea
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-33-2 USPATFULL
CN Benzamide, 3-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L11 ANSWER 8 OF 18 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:171152 USPATFULL
TI Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jaques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., Noth Haven, CT, United States
PI US 2001027202 A1 20011004
AI US 2001-773658 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Arlington Courthouse Plaza I, Suite 1400, 2200 Clarendon Boulevard, Arlington, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-33-2P**, N-(3-tert-Butylphenyl)-N'-(4-(3-(N-methylcarbamoyl)phenoxy)phenyl)urea
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf

kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-33-2 USPATFULL
CN Benzamide, 3-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L11 ANSWER 9 OF 18 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:139616 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wupperal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nashnomya City, Japan
Scott, William J., Gulford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Rena, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 2001016659 A1 20010823
AI US 2001-773672 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3652
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-33-2P**, N-(3-tert-Butylphenyl)-N'-(4-(3-(N-methylcarbamoyl)phenoxy)phenyl)urea
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-33-2 USPATFULL
CN Benzamide, 3-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L11 ANSWER 10 OF 18 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:123628 USPATFULL
TI omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 2001011136 A1 20010802
AI US 2001-773675 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Suite 1400, 2200 Clarendon Blvd., Arlington, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3646
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-33-2P**, N-(3-tert-Butylphenyl)-N'-(4-(3-(N-methylcarbamoyl)phenoxy)phenyl)urea
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-33-2 USPATFULL
CN Benzamide, 3-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L11 ANSWER 11 OF 18 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:123627 USPATFULL
TI Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 2001011135 A1 20010802
AI US 2001-773659 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Suite 1400, Arlington Courthouse Plaza 1, Arlington, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3686
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-33-2P**, N-(3-tert-Butylphenyl)-N'-(4-(3-(N-methylcarbamoyl)phenoxy)phenyl)urea
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-33-2 USPATFULL
CN Benzamide, 3-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L11 ANSWER 12 OF 18 USPATFULL

AB This invention relates to the novel pharmaceutical compositions of Formulas (I) and (II) each of which comprises a compound of Formula (I) or (II) and a pharmaceutically acceptable diluent or carrier. This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I) or (II).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1999:67289 USPATFULL

TI Anti-inflammatory compounds

IN Dixon, James Scott, Malvern, PA, United States
Hall, Ralph Floyd, Villanova, PA, United States
Marshall, Lisa Ann, Wyndmoor, PA, United States
Chilton, III, Floyd H., Pilot Mountain, NC, United States
Mayer, Ruth Judik, Wayne, PA, United States
Winkler, James David, Fort Washington, PA, United States

PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
The Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)

PI US 5912270 19990615
WO 9533712 19951214

AI US 1996-737650 19961122 (8)
WO 1995-US6677 19950602
19961122 PCT 371 date
19961122 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1994-252716, filed on 2 Jun 1994, now patented, Pat. No. US 5470882

DT Utility

FS Granted

EXNAM Primary Examiner: Gerstl, Robert

LREP Dinner, Dara L., Venetianer, Stephen, Kinzig, Charles

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1767

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **447-64-3P**
(prepn. of antiinflammatory ureidophenoxybenzenesulfonates)

RN 447-64-3 USPATFULL

CN Benzenesulfonic acid, 5-(1,1-dimethylpropyl)-2-[4-(trifluoromethyl)-2-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L11 ANSWER 13 OF 18 USPATFULL

AB This invention relates to the novel pharmaceutical compositions of Formulas (I) and (II) each of which comprises a compound of Formula (I) or (II) and a pharmaceutically acceptable diluent or carrier.

This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I) or (II).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 95:105872 USPATFULL

TI Anti-inflammatory compounds

IN Dixon, James S., Malvern, PA, United States
Hall, Raplh F., Villanova, PA, United States
Marshall, Lisa A., Wyndmoor, PA, United States
Chilton, III, Floyd H., Pilot Mountain, NC, United States
Mayer, Ruth J., Wayne, PA, United States
Winkler, James D., Fort Washington, PA, United States

PA SmithKline Beecham Corp., Philadelphia, PA, United States (U.S. corporation)

PI US 5470882 19951128

AI US 1994-252716 19940602 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Dees, Jose G.; Assistant Examiner: Conrad, III, Joseph M.

LREP Dinner, Dara L., Venetianer, Stephen, Lentz, Edward T.

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1612

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **447-64-3**
(anti-inflammatory benzenesulfonic acid derivs., their prepn., and their activity)

RN 447-64-3 USPATFULL

CN Benzenesulfonic acid, 5-(1,1-dimethylpropyl)-2-[4-(trifluoromethyl)-2-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L11 ANSWER 14 OF 18 USPATFULL
AB This invention relates to the novel compounds and pharmaceutical compositions of Formula (I).

This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 95:80325 USPATFULL
TI Anti-inflammatory compounds
IN Adams, Jerry L., Wayne, PA, United States
Hall, Ralph F., Villanova, PA, United States
Seibel, George L., Wayne, PA, United States
PA SmithKline Beecham Corp., Philadelphia, PA, United States (U.S. corporation)
PI US 5447957 19950905
AI US 1994-252851 19940602 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose G.; Assistant Examiner: Barts, Samuel
LREP Dinner, Dara L., Venetianer, Stephen, Lentz, Edward T.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1726
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **171103-10-9P**
(antiinflammatory (ureidophenoxy)benzoic acids and derivs. as inhibitors of phospholipase A2 and CoA-independent transacylase)
RN 171103-10-9 USPATFULL
CN Benzoic acid, 2-[2-[[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L11 ANSWER 15 OF 18 USPATFULL
AB The present invention is directed to novel anticoccidial compositions and methods of employing the same to control coccidiosis in poultry. These compositions comprise a polyether antibiotic and a second component which is a selected carbanilide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 85:38961 USPATFULL
TI Anticoccidial combinations comprising polyether antibiotics and carbanilides
IN O'Doherty, George O. P., Greenfield, IN, United States
Clinton, Albert J., Indianapolis, IN, United States
PI US 4526997 19850702
AI US 1984-611780 19840518 (6)
RLI Division of Ser. No. US 1981-260962, filed on 6 May 1981, now patented, Pat. No. US 4468380 which is a continuation of Ser. No. US 1979-107304, filed on 26 Dec 1979, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Warren, Charles F.; Assistant Examiner: Picard, R. A.
LREP Page, Kathleen R. S., Whale, Arthur R.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 884
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **2063-69-6**
(anticoccidal compns. contg. polyether antibiotics and)
RN 2063-69-6 USPATFULL
CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[4-(4-chlorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 16 OF 18 USPATFULL
AB 1,3,5-Triazinones of the formula ##STR1## where R.sup.1, R.sup.2 and

R.sup.3 have the meanings given in the description, are used for controlling undesirable plant growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 85:23703 USPATFULL
TI 1,3,5-Triazinones and their use for controlling undesirable plant growth
IN Parg, Adolf, Bad Durkheim, Germany, Federal Republic of
Hamprecht, Gerhard, Weinheim, Germany, Federal Republic of
Wuerzer, Bruno, Otterstadt, Germany, Federal Republic of
PA BASF Aktiengesellschaft, Germany, Federal Republic of (non-U.S. corporation)
PI US 4512797 19850423
AI US 1983-462024 19830128 (6)
RLI Continuation-in-part of Ser. No. US 1982-446064, filed on 1 Dec 1982, now abandoned
PRAI DE 1981-3147879 19811203
DT Utility
FS Granted
EXNAM Primary Examiner: Ford, John M.
LREP Keil & Weinkauf
CLMN Number of Claims: 8
ECL Exemplary Claim: 1,8
DRWN No Drawings
LN.CNT 800
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **86607-45-6**
(cyclocondensation of, with acyl isocyanates)
RN 86607-45-6 USPATFULL
CN Urea, N-[5-[2-chloro-4-(trifluoromethyl)phenoxy]-2-nitrophenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 17 OF 18 USPATFULL
AB The present invention is directed to novel anticoccidial compositions and methods of employing the same to control coccidiosis in poultry. These compositions comprise a polyether antibiotic and a second component which is a selected carbanilide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 84:48395 USPATFULL
TI Anticoccidial combinations comprising polyether antibiotics and carbanilides
IN O'Doherty, George O. P., Greenfield, IN, United States
Clinton, Albert J., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 4468380 19840828
AI US 1981-260962 19810506 (6)
RLI Continuation of Ser. No. US 1979-107304, filed on 26 Dec 1979, now abandoned

DT Utility
FS Granted
EXNAM Primary Examiner: Rosen, Sam
LREP Page, Kathleen R. S., Whale, Arthur R.
CLMN Number of Claims: 52
ECL Exemplary Claim: 1,27
DRWN No Drawings
LN.CNT 1366
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **2063-69-6**
(anticoccidal compns. contg. polyether antibiotics and)
RN 2063-69-6 USPATFULL
CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[4-(4-chlorophenoxy)phenyl]-(9CI) (CA INDEX NAME)



L11 ANSWER 18 OF 18 USPATFULL
AB The present invention is directed to novel anticoccidial compositions and methods of employing the same to control coccidiosis in poultry. These compositions comprise a polyether antibiotic and a second component selected from nicarbazin and 4,4'-dinitrocarbanilide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 80:40562 USPATFULL
TI Anticoccidial combinations comprising nicarbazin and the polyether antibiotics
IN Callender, Maurice E., Indianapolis, IN, United States
Jeffers, Thomas K., Greenfield, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 4218438 19800819
AI US 1979-12165 19790214 (6)
DT Utility
FS Granted
EXNAM Primary Examiner: Rosen, Sam
LREP Page, Kathleen R. S., Whale, Arthur R.
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 852
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **2063-69-6**
(anticoccidial compn. contg. polyether antibiotic and)
RN 2063-69-6 USPATFULL
CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[4-(4-chlorophenoxy)phenyl]-(9CI) (CA INDEX NAME)



=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	105.95	710.41

FILE 'CAPLUS' ENTERED AT 15:43:19 ON 10 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 10 Jan 2003 VOL 138 ISS 3
FILE LAST UPDATED: 9 Jan 2003 (20030109/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d his

(FILE 'HOME' ENTERED AT 15:28:08 ON 10 JAN 2003)

FILE 'REGISTRY' ENTERED AT 15:32:39 ON 10 JAN 2003
L1 STRUCTURE UPLOADED
L2 32 S L1
L3 2223 S L1 FUL

FILE 'USPATFULL, USPAT2' ENTERED AT 15:33:20 ON 10 JAN 2003
L4 183 S L3

FILE 'REGISTRY' ENTERED AT 15:36:42 ON 10 JAN 2003
L5 STRUCTURE UPLOADED
L6 50 S L5
L7 1386 S L5 FUL

```
     FILE 'USPATFULL, USPAT2' ENTERED AT 15:37:30 ON 10 JAN 2003
L8          151 S L7

     FILE 'REGISTRY' ENTERED AT 15:40:23 ON 10 JAN 2003
L9               STRUCTURE UPLOADED
L10         195 S L9 FUL

     FILE 'USPATFULL, USPAT2' ENTERED AT 15:40:57 ON 10 JAN 2003
L11          18 S L10

     FILE 'CAPLUS' ENTERED AT 15:43:19 ON 10 JAN 2003

=> s l10
L12         28 L10

=> d abs bib fhitstr 1-28

L12  ANSWER 1 OF 28  CAPLUS  COPYRIGHT 2003 ACS
GI
```



II



III

AB Title compds. B-NHCONH-L-(M-L1)q (I) [B = (un)substituted pyridyl, quinolinyl, isoquinolinyl; L = 5 or 6 membered cyclic structure; L1 = substituted cyclic moiety having at least 5 members; M = bridging group having at least one atom; q = 1-3; with proviso that L and L1 contain 0-4 hetero atoms, e.g., N, O and S] and their pharmaceutically acceptable salts were prepd. For example, coupling of aniline II, e.g., prepd. from Et 3-hydroxybenzoate in 4-steps, with bis(trichloromethyl)carbonate followed by 3-tert-butylaniline afforded urea III. In in vitro raf kinase assays, 112-specific examples of compds. I inhibited kinase activity with IC50 values ranging from 10 nM-10 .mu.M. Compds. I are useful for the treatment of cancerous cell growth mediated by raf kinase.

AN 2002:850357 CAPLUS

DN 137:352907

TI Preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase for the treatment of tumors and/or cancerous cell growth

IN Dumas, Jacques; Riedl, Bernd; Khire, Uday; Wood, Jill E.; Robert, Sibley N.; Monahan, Mary-Katherine; Renick, Joel; Gunn, David E.; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.

PA Bayer Corporation, USA

SO U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 758,548.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002165394	A1	20021107	US 2001-777920	20010207
US 2002137774	A1	20020926	US 2001-907970	20010719
WO 2002062763	A2	20020815	WO 2002-US3361	20020207
WO 2002062763	A3	20021010		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI	US 1999-115877P	P	19990113
	US 1999-257266	B2	19990225
	US 1999-425228	B2	19991022
	US 2001-758548	A2	20010112
	US 2001-777920	A	20010207

OS MARPAT 137:352907
IT **228418-48-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)
RN 228418-48-2 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L12 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2003 ACS
GI



II

AB Title compds., e.g., RNHCONHZOR1 [I; R = C6H4(CMe3)-3, 2-methoxy-5-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 2-methoxy-3-quinolyl, etc.; R1 = (un)substituted acylphenyl, -acylpyridinyl, etc.; Z = (un)substituted 1,3- or -1,4-phenylene] were prepd. Thus, 4-(H2N)C6H4OC6H4(CONHMe)-4 (prepn. given) was condensed with 3-(Me3C)C6H4NH2 and CO(OCCl3)2 to give title compd. II. Data for biol. activity of title compds. were given.

AN 2002:615574 CAPLUS

DN 137:169425

TI Preparation of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors

IN Dumas, Jacques; Riedl, Bernd; Khire, Uday; Wood, Jill E.; Sibley, Robert N.; Monahan, Mary-Katherine; Renick, Joel; Gunn, David E.; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.

PA Bayer Corporation, USA

SO PCT Int. Appl., 125 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062763	A2	20020815	WO 2002-US3361	20020207
	WO 2002062763	A3	20021010		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002165394	A1	20021107	US 2001-777920	20010207
PRAI	US 2001-777920	A	20010207		
	US 1999-115877P	P	19990113		
	US 1999-257266	B2	19990225		
	US 1999-425228	B2	19991022		
	US 2001-758548	A2	20010112		

OS MARPAT 137:169425

IT **228418-48-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors)

RN 228418-48-2 CAPLUS

CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]ami

no]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L12 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2003 ACS
GI



I



II

AB The title compds. [I; E = (un)substituted aryl, heteroaryl; A = aryl, heteroaryl, heterocyclyl; X = S, O, SO2, SO, CH2, CHOH, CO; Z = O, S; p = 0-1; q = 0-1; D = CH, T = CR8, M = C and Q = NT7p, wherein p = 0 and q = 1; or D = CH, T = CR8, M = C and Q = NR7p, wherein p =1 and q = 0, or D = CH, T = CR8, M = C and Q = S or O, wherein q = 0; or D = N, T = CR8, M = C and Q = NR7p, wherein either p or q = 0 and the other = 1; or D = CH, T = N, M = C and Q = NR7p, wherein either p or q = 0 and the other = 1; or D = CH, T = CR8, M = N and Q = CH, wherein q = 0; R1 = alkyl, haloalkyl, aryl, etc.; R2 = H, alkyl, aryl, etc.; R3 = alkylene or alkylene substituted by oxo, and is linked together with N atom to which it is attached and to one of the benzimidazole N atoms to form a heterocyclic compd. fused to the benzimidazole; R7 = H, alkyl, etc.; R8 = H, halo] and their salts, useful in the treatment of hyperproliferative diseases, were prepd. Thus, reacting Me [5-(4-aminophenoxy)-1H-benzimidazol-2-yl]carbamate (prepn. given) with 3-chlorophenyl isocyanate in THF afforded 69% II which showed pIC50 of > 7.0 in TIE-2 and VEGFR2 enzyme assays.

AN 2002:428885 CAPLUS
DN 137:6179
TI Preparation of benzimidazoles as TIE-2 and/or VEGFR2 inhibitors
IN Cheung, Mui; Harris, Philip Anthony; Hasegawa, Masaichi; Ida, Satoru; Kano, Kazuya; Nishigaki, Naohiko; Sato, Hideyuki; Veal, James Martin; Washio, Yoshiaki; West, Rob I.
PA Glaxo Group Limited, UK; Glaxosmithkline K.K.
SO PCT Int. Appl., 217 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002044156	A2	20020606	WO 2001-US44553	20011128
	WO 2002044156	A3	20021017		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002032439	A5	20020611	AU 2002-32439	20011128
PRAI	US 2000-253868P	P	20001129		
	US 2001-310939P	P	20010808		
	WO 2001-US44553	W	20011128		

OS MARPAT 137:6179
IT **433225-93-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of benzimidazoles as TIE-2 and/or VEGFR2 inhibitors)
RN 433225-93-5 CAPLUS
CN Urea, N-[4-(3-amino-4-nitrophenoxy)phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2003 ACS
GI



I



II

AB Title compds. I [n = 1-2 forming a central 5-6 membered (un)satd. carbocyclic ring; m = 0-3; [CH2]mY is attached to said central carbocyclic ring at position 2, 3, or 4; X, Y = carboxamide, thiocarboxamide, ureido, aminosulfonyl, etc.] were prepd. Examples include over 30 compds. synthesized, assays for rotamase inhibition, neuronal cell growth/regeneration, in-vivo protective effects in an animal model of stroke/myocardial infarction (rat) and an in-vivo model of hair growth (mouse). For instance, 3-nitroaniline was reacted with 4-methylphenylsulfonylsulfonyl chloride and 4-methoxyphenylsulfonyl chloride (DMA, Et3N) to give the bis(sulfonamide) as a solid. This intermediate was reduced (EtOHaq, NH4Cl, In.degree., reflux, 4 h) and subsequently treated with 3,5-dichlorophenylisocyanate to give II. II had IC50 = 162 nM for rotamase (a measure of cyclophilin (CyP) A binding). I have an affinity for CyP-type immunophilin proteins and are useful for the treatment of neurol. disorders, hair loss disorders, ischemic disorders, and disorders caused by viral or protozoan infection.

AN 2002:428855 CAPLUS

DN 137:20228

TI Sulfonamido/amido/ureido-phenyl-amides as cyclophilin binding compounds

IN Hamilton, Gregory S.; Belyakov, Sergei; Vaal, Mark; Wei, Ling; Wu, Yong-Qian; Steiner, Joseph P.

PA Guilford Pharmaceuticals Inc., USA

SO PCT Int. Appl., 141 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002044126	A2	20020606	WO 2001-US44449	20011128
	WO 2002044126	A3	20020926		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	AU 2002025767	A5	20020611	AU 2002-25767	20011128
	US 2002127605	A1	20020912	US 2001-994927	20011128
PRAI	US 2000-253074P	P	20001128		
	US 2001-291966P	P	20010521		
	WO 2001-US44449	W	20011128		

OS MARPAT 137:20228

IT **1995-43-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; prepn. of 1,3-disubstituted sulfonamido/amido/ureido-Ph-amides as immunophilin ligands)

RN 1995-43-3 CAPLUS

CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-(3-phenoxyphenyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2003 ACS

AB Chem. structures have been identified which allosterically modify pyruvate kinase and inhibit enzymic activity. These compds. can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, e.g. the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate related to the delivery of oxygen by modifying Hb's oxygen affinity, treatments of tumor and cancer and Alzheimer's disease. Prepn. of e.g. 2-phenylethyloxy-5-formylbenzoic acid is described.

AN 2001:869018 CAPLUS

DN 136:700

TI Allosteric inhibitors of pyruvate kinase for therapeutic use

IN Abraham, Donald J.; Wang, Changging; Danso-Danquah, Richmond; Burnett, James C.; Joshi, Gajanan S.; Hoffman, Steven J.

PA USA

SO U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. 6,214,879.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2001046997	A1	20011129	US 2001-799873	20010307

US 6214879 B1 20010410 US 1998-46643 19980324
PRAI US 1998-46643 A2 19980324
IT **289060-07-7**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyruvate kinase allosteric inhibitors for therapeutic use)
RN 289060-07-7 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[4-(methoxycarbonyl)-2-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, dimethyl ester (9CI) (CA INDEX NAME)



L12 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2003 ACS
GI



I

AB Malarial parasites rely on aspartic proteases called plasmepsins to digest Hb during the intraerythrocytic stage. Plasmepsins from Plasmodium falciparum and Plasmodium vivax have been cloned and expressed for a variety of structural and enzymic studies. Recombinant plasmepsins possess kinetic similarity to the native enzymes, indicating their suitability for target-based antimalarial drug development. We developed an automated assay of P. falciparum plasmepsin II and P. vivax plasmepsin to quickly screen compds. in the Walter Reed chem. database. A low-mol.-mass (346 Da) diphenylurea deriv. [WR268961 (I)] was found to inhibit plasmepsins with a Ki of 1 to 6 .mu.M. This compd. appears to be selective for plasmepsin, since it is a poor inhibitor of the human aspartic protease cathepsin D (Ki greater than 280 .mu.M). I inhibited

the growth of P. falciparum strains W2 and D6, with 50% inhibitory concns. ranging from 0.03 to 0.16 .mu.g/mL, but was much less toxic to mammalian cells. The Walter Reed chem. database contains over 1,500 compds. with a diphenylurea core structure, 9 of which inhibit the plasmepsins, with Ki values ranging from 0.05 to 0.68 .mu.M. These nine compds. show specificity for the plasmepsins over human cathepsin D, but they are poor inhibitors of P. falciparum growth in vitro. Computational docking expts. indicate how diphenylurea compds. bind to the plasmepsin active site and inhibit the enzyme.

AN 2001:623551 CAPLUS
DN 135:327005
TI New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins
AU Jiang, Suping; Prigge, Sean T.; Wei, Lan; Gao, Yu-E.; Hudson, Thomas H.; Gerena, Lucia; Dame, John B.; Kyle, Dennis E.
CS Department of Parasitology, Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD, 20910-7500, USA
SO Antimicrobial Agents and Chemotherapy (2001), 45(9), 2577-2584
CODEN: AMACCQ; ISSN: 0066-4804
PB American Society for Microbiology
DT Journal
LA English
IT **447-79-0**, WR 100081
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(new class of small nonpeptidyl compds. blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins)
RN 447-79-0 CAPLUS
CN Benzenesulfonic acid, 5-chloro-2-[[[[3-chloro-4-(4-chlorophenoxy)phenyl]amino]carbonyl]amino]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2003 ACS
GI



II

AB This invention relates to the prepn. and use of (hetero)aryl ureas ANHCONHB [I; A = L(ML1)q; L = 5- or 6-membered (hetero)aryl, esp. Ph or pyridinyl; M = bridging group; L1 = (hetero)aryl with at least one (un)substituted sulfamoyl, carboxy, or carbamoyl substituent; q = 1-3; B = certain (un)substituted mono- to tricyclic aryl or heteroaryl groups] for the treatment of raf mediated diseases, such as cancer (no data). Approx. 100 invention compds. and numerous intermediates were prepd. For instance, 3-tert-butylaniline was coupled with bis(trichloromethyl)carbonate to form the isocyanate, followed by addn. of 4-(3-N-methylcarbamoylphenoxy)aniline (prepn. given) to afford the urea II.

AN 2000:493516 CAPLUS

DN 133:120157

TI Preparation of .omega.-carboxy(hetero)aryl substituted diphenyl ureas as raf kinase inhibitors

IN Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.

PA Bayer Corporation, USA

SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000042012	A1	20000720	WO 2000-US648	20000112
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1140840	A1	20011010	EP 2000-903239	20000112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 2001011135	A1	20010802	US 2001-773659	20010202
	US 2001011136	A1	20010802	US 2001-773675	20010202
	US 2001016659	A1	20010823	US 2001-773672	20010202
	US 2001027202	A1	20011004	US 2001-773658	20010202
	US 2001034447	A1	20011025	US 2001-773604	20010202
	NO 2001003463	A	20010912	NO 2001-3463	20010712
	US 2002137774	A1	20020926	US 2001-907970	20010719
	US 2002042517	A1	20020411	US 2001-948915	20010910
PRAI	US 1999-115877P	P	19990113		
	US 1999-257266	A2	19990225		
	US 1999-425228	A2	19991022		
	WO 2000-US648	W	20000112		

OS MARPAT 133:120157

IT **284461-33-2P**, N-(3-tert-Butylphenyl)-N'-(4-(3-(N-methylcarbamoyl)phenoxy)phenyl)urea
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)

RN 284461-33-2 CAPLUS

CN Benzamide, 3-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2003 ACS

GI



II

AB The title compds. ADB [I; D = NHCONH; A = substituted moiety of up to 40 carbon atoms of the formula L(ML1)q (wherein L = 5-6 membered cyclic structure; L1 = substituted cyclic moiety having at least 5 members; M = bridging group having al least one atom; q = 1-3; each of L and L1 contains 0-4 members of the group consisting of N, O and S); B = (un)substituted up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D contg. 0-4 members of the group consisting of N, O and S], useful in treating p38 mediated diseases, were prepd. E.g., a multi-step synthesis of the urea II which showed IC50 of 1-10 .mu.M against p38, was given. Compds. I are effective at 0.01-200 mg/kg/day (oral administration).

AN 2000:493376 CAPLUS

DN 133:120155

TI Preparation of .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors

IN Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.

PA Bayer Corporation, USA

SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 2000041698	A1	20000720	WO 2000-US768	20000113
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1158985	A1	20011205	EP 2000-905597	20000113
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1999-115878P	P	19990113		
	US 1999-257265	A2	19990225		
	US 1999-425229	A2	19991022		
	WO 2000-US768	W	20000113		

OS MARPAT 133:120155

IT **228418-48-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of .omega.-carboxy aryl substituted di-Ph ureas as p38 kinase inhibitors)

RN 228418-48-2 CAPLUS

CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2003 ACS

AB A method of treating a p-38 mediated disease other than cancer comprises administration of BNHCONHA [A = (substituted) Ph, pyridyl, 2-thienyl; B = (substituted) aryl, heteroaryl contg. .gtoreq.1 6-membered arom. structure contg. 0-4 N, O, or S atoms]. Thus, 5-tert-butyl-2-(3-tetrahydrofuranyloxy)aniline (prepn. given) and p-tolyl isocyanate were stirred 8 h in PhMe to give 75% N-(5-tert-butyl-2-(3-tetrahydrofuranyloxy)phenyl)-N'-(4-methylphenyl)urea. Title compds. inhibited p38 kinase with IC50 = 1-10 .mu.M.

AN 1999:421667 CAPLUS

DN 131:58659

TI Preparation of diaryl ureas as inhibitors of p38 kinase.

IN Miller, Scott; Osterhout, Martin; Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood,

Jill E.; Gunn, David; Hatoum-Mokdad, Holia; Rodriguez, Mareli; Sibley, Robert; Wang, Ming
PA Bayer Corporation, USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9932463	A1	19990701	WO 1998-US27265	19981222
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2315715	AA	19990701	CA 1998-2315715	19981222
AU 9919399	A1	19990712	AU 1999-19399	19981222
EP 1042305	A1	20001011	EP 1998-964221	19981222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001526276	T2	20011218	JP 2000-525400	19981222
PRAI US 1997-995749	A	19971222		
WO 1998-US27265	W	19981222		

OS MARPAT 131:58659
IT **228399-38-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of diaryl ureas as inhibitors of p38 kinase)
RN 228399-38-0 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-(4-methoxyphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2003 ACS
GI



I



II

AB The invention relates to 1,3-disubstituted ureas I [R1 = (un)substituted aryl; R2 = NO2, NH2; X = O, S], and a method of prepg. them by treating arom. amines with isocyanates. The isocyanates may be formed in situ, and the reaction carried out in a solvent such as toluene, at, e.g., 80.degree.C. If a nitro group is formed, it may be reduced with H2 in the presence of a Pd catalyst to give an amino group. The obtained 1,3-disubstituted ureas are inhibitors of the activity of the enzyme acyl co-enzyme A:cholesterol acyltransferase (ACAT), and may be used to inhibit cholesterol esterification and absorption in hypercholesterolemia. For instance, reaction of 4-(4'-nitrophenoxy)aniline with 2,5-difluorophenyl isocyanate gave 76% title compd. II. The latter gave 49% inhibition of rat liver ACAT at 2 .mu.M, and 58% inhibition of ACAT in rabbit intestinal mucosa, at the same concn., both in vitro.

AN 1999:421643 CAPLUS

DN 131:73441

TI 1,3-Disubstituted ureas useful as ACAT inhibitors, and method for their preparation

IN Oremus, Vladimir; Smahovsky, Vendelin; Faberova, Viera; Kakalik, Ivan; Schmidtova, Ludmila; Zemanek, Marian

PA Slovako- Farma, A.S., Slovakia

SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932437	A1	19990701	WO 1998-SK19	19981216
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9916976	A1	19990712	AU 1999-16976	19981216
	EP 1042278	A1	20001011	EP 1998-961715	19981216
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
	JP 2001526259	T2	20011218	JP 2000-525374	19981216
	US 6444691	B1	20020903	US 2000-581821	20000710
PRAI	SK 1997-1751	A	19971219		
	WO 1998-SK19	W	19981216		

OS MARPAT 131:73441
IT **228544-40-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1,3-disubstituted ureas as ACAT inhibitors)
RN 228544-40-9 CAPLUS
CN Urea, N-[4-(4-nitrophenoxy)phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2003 ACS
GI



II

AB The invention relates to the use of a group of aryl ureas ANHCONHB [I; A = certain (un)substituted Ph, pyridinyl, or thien-2-yl groups; B = certain (un)substituted mono- to tricyclic aryl or heteroaryl groups] in treating raf-mediated diseases, and pharmaceutical compns. for use in such therapy. A subset of I are novel and are claimed per se. Approx. 160 invention compds. and numerous intermediates were prepd. For instance, reaction of tolyl isocyanate with 2-methoxy-5-(trifluoromethanesulfonyl)aniline in EtOAc gave title compd. II. In an in vitro raf kinase assay, all compds. displayed IC50 values between 1 nM and 10 .mu.M.
AN 1999:421642 CAPLUS
DN 131:58658
TI Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
IN Miller, Scott; Osterhout, Martin; Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Gunn, David; Rodriguez, Mareli; Wang, Ming
PA Bayer Corporation, USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932436	A1	19990701	WO 1998-US26081	19981222
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2315646	AA	19990701	CA 1998-2315646	19981222
	AU 9919054	A1	19990712	AU 1999-19054	19981222
	EP 1049664	A1	20001108	EP 1998-963809	19981222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001526258	T2	20011218	JP 2000-525373	19981222
	BR 9814375	A	20020521	BR 1998-14375	19981222
	NO 2000003230	A	20000821	NO 2000-3230	20000621
PRAI	US 1997-996344	A	19971222		
	WO 1998-US26081	W	19981222		

OS MARPAT 131:58658
IT **228399-38-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sym. and unsym. substituted di-Ph ureas with inhibitory effects on tumors mediated by raf kinase)
RN 228399-38-0 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-(4-methoxyphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2003 ACS
AB Sodium 2-[2-[3-[4-chloro-3-(trifluoromethyl)phenyl]ureido]-4-(trifluoromethyl)phenoxy]-4,5-dichlorobenzenesulfonate was prepd. in 5 steps from 3,4-dichlorophenol and 4-chloro-3-nitrobenzotrifluoride. Also prepd. were sodium 2-[2-[3-[3,5-bis(trifluoromethyl)phenyl]ureido]-4-(trifluoromethyl)phenoxy]-5-(1,1-dimethylpropyl)benzenesulfonate and sodium 2-[2-[3-[4-chloro-3-(trifluoromethyl)phenyl]ureido]-4-(trifluoromethyl)phenoxy]-5-(1,1-dimethylpropyl)benzenesulfonate. For ear edema induced in the mouse by 12-O-tetradecanoylphorbol 13-acetate at 50 mg/ear topically, 2-[2-[3-[4-chloro-3-(trifluoromethyl)phenyl]ureido]-4-(trifluoromethyl)phenoxy]-5-(1,1-dimethylpropyl)benzenesulfonic acid

exhibited an ED50 of 0.32 mg/ear and 2-[2-[[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl]amino]-4-(trifluoromethyl)phenoxy]-5-(1,1-dimethylpropyl)benzenesulfonic acid exhibited an ED50 of 0.87 mg/ear.

AN 1999:384012 CAPLUS
DN 131:44661
TI Anti-inflammatory compounds
IN Dixon, James Scott; Hall, Ralph Floyd; Marshall, Lisa Ann; Chilton, Floyd H., III; Mayer, Ruth Judik; Winkler, James David
PA Smithkline Beecham Corporation, USA; The Johns Hopkins University
SO U.S., 17 pp., Cont.-in-part of U.S. 5,470,882.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5912270	A	19990615	US 1996-737650	19961122
US 5470882	A	19951128	US 1994-252716	19940602
WO 9533712	A1	19951214	WO 1995-US6677	19950602

W: JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRAI US 1994-252716 19940602
WO 1995-US6677 19950602
OS MARPAT 131:44661
IT **447-64-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of antiinflammatory ureidophenoxybenzenesulfonates)
RN 447-64-3 CAPLUS
CN Benzenesulfonic acid, 5-(1,1-dimethylpropyl)-2-[4-(trifluoromethyl)-2-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2003 ACS
AB CoA-independent transacylase (CoA-IT) inhibitors are disclosed for inhibiting or reducing cell proliferation in a human or mammal. Compds. for inhibiting proliferation or inducing apoptosis exclude 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine (I) or alkyl lysophospholipid analogs, but the I and analogs are disclosed for

treatment of other CoA-IT-mediated diseases. Prepn. of e.g. di-Et 7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptanephosphonate (II) is described. II inhibited CoA-IT at a concn. of 9 .mu.M; II also showed apoptosis-inducing activity. The specific inhibition of CoA-IT by I is also described.

AN 1997:207756 CAPLUS
DN 126:195233
TI Compounds for inhibition of CoA-independent transacylase, induction of apoptosis, treating CoA-independent transacylase-dependent diseases, and inhibiting cell proliferation
IN Winkler, James David; Chilton, Floyd Iii
PA Smithkline Beecham Corporation, USA; Wake Forrest University; Winkler, James David; Chilton, Floyd Iii
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9704765	A1	19970213	WO 1996-US12257	19960724
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 841910	A1	19980520	EP 1996-925501	19960724
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	JP 11511130	T2	19990928	JP 1996-507752	19960724
PRAI	US 1995-2239P	P	19950725		
	WO 1996-US12257	W	19960724		

IT **173730-67-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compds. for inhibition of CoA-independent transacylase, induction of apoptosis, treating CoA-independent transacylase-dependent diseases and inhibiting cell proliferation, and compd. prepn.)
RN 173730-67-1 CAPLUS
CN Benzenesulfonic acid, 4,5-dichloro-2-[2-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-4-(trifluoromethyl)phenoxy]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

L12 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2003 ACS

AB ET-18-O-CH3 (1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine) is an antiproliferative agent, blocking the growth of cancer cells both in vitro and in vivo. However, there is controversy regarding the mechanism leading to its antiproliferative effects. CoA-independent transacylase (CoA-IT) is an enzyme that remodels arachidonate between specific phospholipid donor and acceptor mols. in a variety of mammalian cells. ET-18-O-CH3 was a potent inhibitor of CoA-IT (IC50, 0.5 .mu.M), and kinetic anal. revealed that its inhibition was competitive with the lyso-phospholipid substrate. The goal of the current study was to explore the connection between inhibition of CoA-IT and antiproliferative effects using several structurally distinct inhibitors of CoA-IT. ET-18-O-CH3 and other inhibitors of CoA-IT were found to inhibit cell proliferation and thymidine incorporation into the DNA, as well as to induce apoptosis in human HL-60 monocytic leukemia cells. The mechanism of apoptosis induced by ET-18-O-CH3 appeared to be different from that induced by tumor necrosis factor; the former failed to activate NF-.kappa.B, whereas tumor necrosis factor did. Closer examn. of the pharmacol. of apoptosis in this model revealed that compds. that were structurally related to CoA-IT inhibitors, but lacked CoA-IT inhibitory activity, also failed to induce apoptosis. In addn., compds. that inhibited other enzymes that participate in arachidonic acid metab., cyclooxygenase, 5-lipoxygenase and phospholipase A2, did not induce apoptosis. Taken together, these results demonstrate that inhibition of CoA-IT can be linked to blockade of proliferation and the induction of apoptosis in HL-60 cells.

AN 1996:702444 CAPLUS

DN 126:166148

TI Inhibitors of coenzyme A-independent transacylase induce apoptosis in human HL-60 cells

AU Winkler, James D.; Eris, Tamer; Sung, Chiu-Mei; Chabot-Fletcher, Marie; Mayer, Ruth J.; Surette, Marc E.; Chilton, Floyd H.

CS Dep. Immunopharmacol. Med. Chem., SmithKline Beecham Pharmaceuticals, King of Prussia, PA, USA

SO Journal of Pharmacology and Experimental Therapeutics (1996), 279(2), 956-966
CODEN: JPETAB; ISSN: 0022-3565

PB Williams & Wilkins

DT Journal

LA English

IT **162793-63-7**, Skf 45905
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors of CoA-independent transacylase induce apoptosis in human HL-60 cells)

RN 162793-63-7 CAPLUS

CN Benzenesulfonic acid, 4,5-dichloro-2-[2-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-4-(trifluoromethyl)phenoxy]-(9CI) (CA INDEX NAME)



L12 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2003 ACS
GI



I

AB The invention relates to the novel compds. and pharmaceutical compns. of I [R1 = SO3H, S(O)n-C1-4 alkyl; n = 0-2; R2 = H, halo, (substituted) C1-8 alkyl, C1-8 alkoxy; m = 1, 2; R3 = C(O)R7, C(S)R7; R4, R8, R9 = H, C1-4 alkyl; R5 = H, halo, CF3, Me, (CH2)tC(O)2R8, (CH2)tOH; t = 0-2; R6 = H, halo; R7 = (substituted) aryl, (substituted) aryl-C1-2 alkyl, (substituted) C1-8 alkyl, NR9R10; R10 = (substituted) aryl, (substituted) aryl-C1-2 alkyl, (substituted) C1-8 alkyl, or R9NR10 form 5- to 7-membered (un)satd. ring with optional addnl. heteroatom of O/N or S; X = O, S; with provisions] and pharmaceutically acceptable salts thereof. The invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amt. of a compd. or compn. of I. Prepn. of selected compds. of the invention is described. Compds. of the invention demonstrated phospholipase A2 inhibition, generally at 50 .mu.M levels.

AN 1996:137693 CAPLUS
DN 124:165248
TI Aryl antiinflammatory compounds, their preparation, and their activity
IN Adams, Jerry Leroy; Hall, Ralph Floyd
PA SmithKline Beecham Corp., USA
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9533458	A1	19951214	WO 1995-US6961	19950602

W: JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRAI US 1994-252718 19940602
OS MARPAT 124:165248
IT **174083-25-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(aryl antiinflammatory compd. prepn. and activity)
RN 174083-25-1 CAPLUS
CN Benzenesulfonic acid, 5-(1,1-dimethylpropyl)-2-[2-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-4-(trifluoromethyl)phenoxy]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

L12 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2003 ACS
GI



I



II

AB Pharmaceutical compns. are disclosed which contain I (R1 = Cl; R2 = H, Cl, R3 = Cl, CF3; R4 = Ph substituted at 1-2 positions with Cl or CF3; when R1

and R2 are both Cl, then R3 = CF3) or II [R1 = Cl, C((CH3)2)CH2CH3; R2 = H, Cl, Me; R5 = H, Cl; R3 = Cl, CF3; R4 = Ph substituted at 1-2 positions with Cl or CF3, or disubstituted Ph substituted once by Cl or CF3 and once by 3-chlorophenoxy or 4-chlorophenoxy; with provisions] and a pharmaceutically acceptable diluent or carrier. Also disclosed is a method for treating or reducing inflammation in a mammal by administering an effective amt. of a compd. or compn. of I or II. Prepn. and activity of selected compds. of the invention are included.

AN 1996:13285 CAPLUS
DN 124:165243
TI Anti-inflammatory benzenesulfonic acid derivatives, their preparation, and their activity
IN Dixon, James S.; Hall, Raplh F.; Marshall, Lisa A.; Chilton, Floyd H., III; Mayer, Ruth J.; Winkler, James D.
PA SmithKline Beecham Corp., USA
SO U.S., 16 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5470882	A	19951128	US 1994-252716	19940602
	WO 9533712	A1	19951214	WO 1995-US6677	19950602
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 765305	A1	19970402	EP 1995-922898	19950602
	EP 765305	B1	19991215		
	R: BE, CH, DE, FR, GB, IT, LI, NL				
	JP 10506092	T2	19980616	JP 1995-501061	19950602
	US 5912270	A	19990615	US 1996-737650	19961122
PRAI	US 1994-252716		19940602		
	WO 1995-US6677		19950602		

OS MARPAT 124:165243
IT **447-64-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-inflammatory benzenesulfonic acid derivs., their prepn., and their activity)
RN 447-64-3 CAPLUS
CN Benzenesulfonic acid, 5-(1,1-dimethylpropyl)-2-[4-(trifluoromethyl)-2-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L12 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2003 ACS
GI



I

AB This invention relates to the novel compds. and pharmaceutical compns. of formula I wherein R1 is (CH2)nOH or (CH2)nCO2R8 ; n is 0 or an integer having a value of 1; X is oxygen or sulfur; R2 is hydrogen, halogen, optionally substituted C1-8 alkyl, or C1-8 alkoxy; m is an integer having a value of 1 or 2; R3 is C(O)R7 ; R4 is hydrogen, or C1-4 alkyl; R5 is hydrogen, halogen, CF3, CH3, (CH2)tCO2R9, or (CH2)tOH; t is 0 or an integer having a value of 1 or 2; R6 is hydrogen or halogen; R7 is NR9R10 ; R8 is hydrogen or C1-4 alkyl; R9 is hydrogen or C1-4 alkyl; R10 is hydrogen, optionally substituted aryl, optionally substituted arylC1-2 alkyl, optionally substituted C1-8 alkyl, or together R9 and R10 with the nitrogen to which they are attached form a 5 to 7 membered satd. or unsatd. ring which may optionally comprise an addnl. heteroatom selected from O/N or sulfur; or a pharmaceutically acceptable salt thereof. This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amt. of a compd. or compn. of I. Thus, e.g., benzhydrol 2-[2-[3-(4-bromophenyl)ureido]-4-(trifluoromethyl)phenoxy]benzoate (prepn. given) was hydrogenated over 10% Pd/C to afford 2-[2-[3-(4-bromophenyl)ureido]-4-(trifluoromethyl)phenoxy]benzoic acid which inhibited PLA2 and CoA-IT at 50 .mu.M or less.

AN 1995:838690 CAPLUS
DN 124:8418
TI Antiinflammatory (ureidophenoxy)benzoic acids and derivatives as inhibitors of phospholipase A2 and CoA-independent transacylase
IN Adams, Jerry L.; Hall, Ralph F.; Seibel, George L.
PA SmithKline Beecham Corp., USA
SO U.S., 17 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5447957	A	19950905	US 1994-252851	19940602
	WO 9533460	A1	19951214	WO 1995-US6680	19950602
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 1994-252851		19940602		

OS MARPAT 124:8418
IT **171103-10-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiinflammatory (ureidophenoxy)benzoic acids and derivs. as inhibitors of phospholipase A2 and CoA-independent transacylase)

RN 171103-10-9 CAPLUS

CN Benzoic acid, 2-[2-[[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L12 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2003 ACS

AB The enzyme CoA-independent transacylase (CoA-IT) has been proposed to mediate the movement of arachidonate between specific phospholipid subclasses, and we have shown that two inhibitors of CoA-IT (SK&F 98625 and SK&F 45905) block this movement. In this report, we use these inhibitors to further characterize the role of CoA-IT in the prodn. of lipid mediators. SK&F 98625 (di-Et 7-(3,4,5-triphenyl-2-oxo-2,3-dihydro-imidazol-1-yl)heptane-phosphonate) and SK&F 45905 (2-[2-[3-(4-chloro-3-trifluoromethylphenyl)ureido]-4-trifluoromethyl phenoxy]-4,5-dichlorobenzenesulfonic acid) inhibited CoA-IT activity (IC50 values of 9 .mu.M and 6 .mu.M, resp.). Neither compd. had any effect on cyclooxygenase, 14-kDa PLA2 or acetyltransferase activities at concns. below 20 .mu.M. However, SK&F 45905 inhibited 85-kDa PLA2 activity (IC50 = 3 .mu.M), and both compds. inhibited 5-lipoxygenase activity (IC50 values of 2-4 .mu.M). In ionophore-stimulated neutrophils, SK&F 98625 and SK&F 45905 blocked the liberation of arachidonic acid from phospholipids, which suggests that the movement of arachidonate into specific phospholipid pools is a prerequisite for release. Both compds. also inhibited the prodn. of platelet-activating factor in ionophore-stimulated neutrophils and antigen-stimulated mast cells. This inhibition of platelet-activating factor and arachidonic acid release was not mimicked by an inhibitor of 5-lipoxygenase, zileuton, which indicates that the primary mode of action of SK&F 98625 and SK&F 45905 is via inhibition of CoA-IT. SK&F 98625 and SK&F 45905 were able to decrease prostaglandin prodn. in several inflammatory cells and to block signs of inflammation in ears of phorbol ester-challenged mice. Taken together, these results show that blockade of CoA-IT, which leads to inhibition of arachidonate remodeling between phospholipids, results in the attenuation of platelet-activating factor prodn., arachidonic acid release and the formation of eicosanoid products.

AN 1995:828039 CAPLUS

DN 123:275438

TI Effects of CoA-independent transacylase inhibitors on the production of lipid inflammatory mediators

AU Winkler, James D.; Fonteh, Alfred N.; Sung, Chiu-Mei; Heravi, Javid D.; Nixon, Andrew B.; Chabot-Fletcher, Marie; Griswold, Don; Marshall, Lisa

A.; Chilton, Floyd H.
CS Div. Pharmacol., SmithKline Beecham Pharm., King of Prussia, PA, USA
SO Journal of Pharmacology and Experimental Therapeutics (1995), 274(3), 1338-47
CODEN: JPETAB; ISSN: 0022-3565
PB Williams & Wilkins
DT Journal
LA English
IT **162793-63-7**, SKF 45905
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(effects of CoA-independent transacylase inhibitors on the prodn. of lipid inflammatory mediators)
RN 162793-63-7 CAPLUS
CN Benzenesulfonic acid, 4,5-dichloro-2-[2-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-4-(trifluoromethyl)phenoxy]-(9CI) (CA INDEX NAME)



L12 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2003 ACS
AB The enzyme CoA-independent transacylase (CoA-IT) has been proposed to mediate the movement of arachidonate between phospholipid subclasses and influence the formation of arachidonic acid metabolites and platelet-activating factor. To substantiate the crit. role of CoA-IT, the authors have developed two structurally diverse inhibitors of CoA-IT activity, SK&F 98625 [diethyl 7-(3,4,5-triphenyl-2-oxo-2,3-dihydro-imidazole-1-yl)heptane phosphonate] and SK&F 45905 [[2-[2-(4-chloro-3-(trifluoromethyl)phenyl)ureido]-4-(trifluoromethyl)phenoxy]-4,5-dichlorobenzenesulfonic acid]. These compds. were tested for their capacity to block microsomal CoA-IT activity using two assay systems, the transacylation of 1-alkyl-2-lyso-sn-glycero-3-phosphocholine (GPC) and the transfer of [14C]arachidonate from 1-acyl-2-[14C]arachidonoyl-GPC to lyso-PE. Both SK&F 98625 and SK&F 45905 inhibited CoA-IT activity (IC50s 6-19 .mu.M) in these two assays. In contrast, SK&F 98625 or SK&F 45905 had little or no effect on other lipid-modifying activities, including CoA-dependent acyltransferase or acetyltransferase. Kinetic anal. revealed that both SK&F 98625 and SK&F 45905 interact directly with the enzyme and prevented the acylation of lysophospholipids in a competitive manner. In intact human neutrophils, both SK&F 98625 and SK&F 45905 completely blocked the movement of [3H]arachidonate from 1-acyl-linked

phospholipids into 1-alkyl-2-arachidonoyl-GPC and 1-alk-1'-enyl-2-arachidonoyl-GPE. In contrast, these compds. did not inhibit the incorporation of free arachidonic acid into cellular lipids indicating that they did not alter CoA-dependent acyl transferase activities in the intact cell. This is the first report to utilize an inhibitor to address the importance of CoA-IT in arachidonate-phospholipid remodeling. These results provide further evidence that CoA-IT mediates the movement of arachidonate into the large pools of 1-ether-linked phospholipids in human neutrophils and suggest that it may be possible to regulate AA levels in cellular phospholipids with CoA-IT inhibitors.

AN 1995:495264 CAPLUS
DN 122:259557
TI Inhibitors of CoA-independent transacylase block the movement of arachidonate into 1-ether-linked phospholipids of human neutrophils
AU Chilton, Floyd H.; Fonteh, Alfred N.; Sung, Chiu-Mei; Hickey, Deirdre M. B.; Torphy, Theodore J.; Mayer, Ruth J.; Marshall, Lisa A.; Heravi, Javid D.; Winkler, James D.
CS Section on Pulmonary and Critical Care Medicine, Bowman Gray School of Medicine, Winston-Salem, NC, 27157-1054, USA
SO Biochemistry (1995), 34(16), 5403-10
CODEN: BICHAW; ISSN: 0006-2960
PB American Chemical Society
DT Journal
LA English
IT **162793-63-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors of CoA-independent transacylase block movement of arachidonate into 1-ether-linked phospholipids of human neutrophils)
RN 162793-63-7 CAPLUS
CN Benzenesulfonic acid, 4,5-dichloro-2-[2-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-4-(trifluoromethyl)phenoxy]-(9CI) (CA INDEX NAME)



L12 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2003 ACS
GI



I

AB The title material contains a phenol cyan coupler, which is 2-substituted with a ureido group Q1 and 5-substituted with R1Q2SO2R2CONH [Q2 = NR4, O; R1 = (cyclo)alkyl, aryl, heterocycle; R2 = alkylene; R3 = H, substituent; n = 1-4; R4 = H, alkyl, aryl, heterocycle; R5 = H, substituent except CN]. Thus, a soln. of the title cyan coupler I in di-Bu phthalate and EtOAc contg. alkyl naphthalenesulfonate and gelatin was mixed with a red-sensitive AgBr emulsion then coated onto a polyester support to give a photog. film, which gave fog-free printed image with coloring property.

AN 1991:618758 CAPLUS
DN 115:218758
TI Silver halide color photographic emulsion material containing ureido-substituted phenol cyan coupler
IN Nakayama, Noritaka; Masukawa, Toyoaki
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03080244	A2	19910405	JP 1989-219170	19890824

PRAI JP 1989-219170 19890824
IT **136925-86-5**
RL: USES (Uses)
(cyan coupler, for silver halide photog. emulsion, prevention of fog in)
RN 136925-86-5 CAPLUS
CN Butanamide, 2-[(decylamino)sulfonyl]-N-[5-hydroxy-2-(4-methoxyphenoxy)-4-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2003 ACS
GI



I

AB The title compds. [I; R1 = H, cyano, CF3; R2, R4, R5 = H, halo; R3 = halo, CF3, CF3O, CF3SO2; R6 = NR7R8, CH2CHR11CO2R12; R7, R8 = H, alkoxycarbonylethyl, COR9, SO2R10; R9 = (un)substituted alkyl, alkenyl, alkynyl, Ph(CH2), naphthyl, pyridyl, furyl, PhS, alkylamino, etc.; R10 = (un)substituted alkyl, Ph, naphthyl, pyridyl, thienyl; R11 = H, halo; R12 = alkyl] were prepd. as herbicides and plant growth regulators (no data), e.g., by etherification of amino(hydroxy)benzonitriles with halobenzenes. Thus, 3,4,5-trichlorobenzotrifluoride in DMSO was added dropwise to a pre-stirred mixt. of 2-amino-4-hydroxybenzonitrile and NaOH in DMSO and the whole was stirred for 5 h at 50.degree. and 2 h at 90.degree. to give 85% title compd. I (R1 = R5 = Cl, R2 = R4 = H, R3 = CF3, R6 = NH2).
AN 1991:101367 CAPLUS
DN 114:101367
TI Preparation of phenoxybenzonitriles as herbicides and plant growth regulators
IN Busse, Ulrich; Santel, Hans Joachim; Schmidt, Robert R.; Luerssen, Klaus; Strang, Harry
PA Bayer A.-G., Germany
SO Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 379915	A1	19900801	EP 1990-100701	19900113

R: BE, CH, DE, FR, GB, IT, LI, NL
JP 02233655 A2 19900917 JP 1990-11973 19900123
PRAI DE 1989-3902288 19890126
OS MARPAT 114:101367
IT **132147-05-8P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as herbicide and plant growth regulator)
RN 132147-05-8 CAPLUS
CN Urea, N-[2-cyano-5-[2,6-dichloro-4-(trifluoromethyl)phenoxy]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2003 ACS
AB Coccidiosis in poultry is controlled by oral administration of a polyether antibiotic in combination with a carbanilide or a thiocarbanilide in feeding materials. A no. of feed compns. are given to which monensin [17090-79-8] and a carbonitrile such as 3,3'-bis(trifluoromethyl)-4,4'-dichlorocarbanilide [370-50-3] may be added. A large no. of combinations were evaluated in chickens infected with oocysts of Eimeria cervulina and E. tenella. The combinations gave superior anticoccidal efficacy to the compds. alone. The compds. were prepd., e.g., by reaction of 3-nitro-5-(trifluoromethyl)-o-phenylenediamine [2078-01-5] with 2,4-dimethylphenyl isocyanate [51163-29-2] which gave 2-amino-3-nitro-5-(trifluoromethyl)-2',4-dimethylcarbanilide [76393-19-6].
AN 1985:100800 CAPLUS
DN 102:100800
TI Anticoccidial combinations comprising polyether antibiotics and carbanilides
IN O'Doherty, George O. P.; Clinton, Albert J.
PA Lilly, Eli, and Co. , USA
SO Can., 54 pp.
CODEN: CAXXA4
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 1171782	A1	19840731	CA 1980-367322	19801222
	US 4468380	A	19840828	US 1981-260962	19810506
	US 4526997	A	19850702	US 1984-611780	19840518
PRAI	US 1979-107304		19791226		
	US 1981-260962		19810506		

OS CASREACT 102:100800
IT **2063-69-6**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anticoccidal compns. contg. polyether antibiotics and)
RN 2063-69-6 CAPLUS

CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[4-(4-chlorophenoxy)phenyl]-
(9CI) (CA INDEX NAME)



L12 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2003 ACS
GI



I

AB Triazinetriones I [R = (un)substituted alkyl, alkenyl, cycloalkyl, Ph; R1 = H, alkyl, acyl, alkali metal, ammonium; R2 = halo, cyano, NO2; R3 = substituted Ph] were prepd. by cyclocondensing a phenoxyphenylurea with R4CONCO (R4 = halo, alkoxy, aryloxy). Thus, N-[3-[2-chloro-4-(trifluoromethyl)phenoxy]-6-nitrophenyl]-N1-methylurea was treated with ClCONCO to give 83% I (R = Me, R1 = H, R2 = NO2, R3 = 2,4-Cl(F3C)C6H3). I are effective herbicides at 0.125-3.0 kg/ha.

AN 1983:488238 CAPLUS
DN 99:88238
TI 1,3,5-Triazinones and their use for controlling undesired plant growth
IN Parg, Adolf; Hamprecht, Gerhard; Wuerzer, Bruno
PA BASF A.-G. , Fed. Rep. Ger.
SO Ger. Offen., 55 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3147879	A1	19830616	DE 1981-3147879	19811203
	EP 81142	A2	19830615	EP 1982-110859	19821124
	EP 81142	A3	19840411		
	EP 81142	B1	19860625		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	JP 58103374	A2	19830620	JP 1982-204703	19821124
	CA 1185974	A1	19850423	CA 1982-416267	19821124
	AT 20528	E	19860715	AT 1982-110859	19821124
	BR 8206946	A	19831011	BR 1982-6946	19821130
	ZA 8208857	A	19831026	ZA 1982-8857	19821202
	HU 30900	O	19840428	HU 1982-3882	19821202

HU 188336 B 19860428
US 4512797 A 19850423 US 1983-462024 19830128
PRAI DE 1981-3147879 19811203
DE 1982-3201229 19820116
EP 1982-110859 19821124
US 1982-446064 19821201
OS CASREACT 99:88238

IT **86810-56-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation of, with acyl isocyanates)

RN 86810-56-2 CAPLUS
CN Urea, N-[3-[2-chloro-4-(trifluoromethyl)phenoxy]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2003 ACS
GI



I

AB The title compds. [I; R = halo, NO2, cyano, optionally halogen-substituted alkyl, akoxy, alkylthio, alkylsulfinyl, alkylsulfonyl; R1, R2 = alkyl, haloakyl, alkoxy, halo, NO2, cyano, CO2H; R3 = H, halo, cyano, NO2; R4 = halo, (un)substituted alkyl, alkenyl, cycloalkyl, Ph; R5 = H, alkyl, haloacyl, alkali metal, ammonium] were prepd. by cyclocondensing (phenoxyphenyl)ureas with acyl isocyanates. Thus, N-[2-[2-chloro-4-(trifluoromethyl)phenoxy]-2-nitrophenyl]-N1-methylurea was treated with ClCONCO to give 83% I (R = F3C, R1 = 2-Cl, R2 = R5 = H, R3 = NO2,. R4 = Me). I are better herbicides against, e.g., Chenopodium album, than 1-[4-[2-chloro-4-(trifluoromethyl)phenoxy]phenyl-3-methyl-1,3,5-triazine-2,4,6(1H,3H,5H)-trione.

AN 1983:470773 CAPLUS
DN 99:70773
TI 1,3,5-Triazinones and their use in combating undesired plant growth
IN Parg, Adolf; Hamprecht, Gerhard; Wuerzer, Bruno
PA BASF A.-G. , Fed. Rep. Ger.
SO Eur. Pat. Appl., 42 pp.
CODEN: EPXXDW
DT Patent
LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 81142	A2	19830615	EP 1982-110859	19821124
	EP 81142	A3	19840411		
	EP 81142	B1	19860625		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	DE 3147879	A1	19830616	DE 1981-3147879	19811203
	DE 3201229	A1	19830728	DE 1982-3201229	19820116
	AT 20528	E	19860715	AT 1982-110859	19821124
PRAI	DE 1981-3147879		19811203		
	DE 1982-3201229		19820116		
	EP 1982-110859		19821124		

OS CASREACT 99:70773

IT **86607-45-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation of, with acyl isocyanates)

RN 86607-45-6 CAPLUS

CN Urea, N-[5-[2-chloro-4-(trifluoromethyl)phenoxy]-2-nitrophenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2003 ACS

GI



I

AB Anticoccidial compns. such as feedstuffs or premixes for poultry such as chicken or turkey contain a combination of a polyether antibiotic and a carbanilide I (R1, R2, and R3 = H, halogen, CN, NH2, NO2, C1-6 alkyl, C2-4 alkanoylamino, C1-4 alkylthio, substituted phenoxy, etc.; R4 and R5 = H or C1-4 alkyl; R6, R7, and R8 = H, halogen, CN, NH2, C2-4 haloalkenyloxy, etc.). Thus, a premix contg. 2-amino-2'-chloro-3,4'-dinitro-5-(trifluoromethyl)carbanilide [76393-24-3] and monensin [17090-79-8] each at 50 ppm effectively controlled coccidiosis in 1-wk broiler chicks infected with Eimeria acervulina and E. tenella.

AN 1981:71498 CAPLUS

DN 94:71498

TI Anticoccidial composition and carbanilides

IN Callender, Maurice Emerson; Jeffers, Thomas Kirk; O'Doherty, George Oliver Plunkett; Clinton, Albert James

PA Lilly, Eli, and Co., USA

SO Eur. Pat. Appl., 93 pp.

CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 15110	A2	19800903	EP 1980-300387	19800211
	EP 15110	A3	19820811		
	EP 15110	B1	19850821		
	R: BE, CH, DE, FR, GB, IT, LU, NL, SE				
	US 4218438	A	19800819	US 1979-12165	19790214
	GB 2044099	A	19801015	GB 1980-4472	19800211
	AU 8055465	A1	19800828	AU 1980-55465	19800212
	AU 531681	B2	19830901		
	ZA 8000791	A	19810930	ZA 1980-791	19800212
	IL 59373	A1	19840330	IL 1980-59373	19800212
	BE 881689	A1	19800813	BE 1980-9718	19800213
	DK 8000612	A	19800815	DK 1980-612	19800213
	JP 55120513	A2	19800917	JP 1980-17196	19800213
	JP 01047443	B4	19891013		
	FR 2456520	A1	19801212	FR 1980-3179	19800213
	FR 2456520	B1	19830805		
	ES 488543	A1	19801216	ES 1980-488543	19800213
	AT 8000762	A	19820715	AT 1980-762	19800213
	AT 369988	B	19830225		
	CA 1136046	A1	19821123	CA 1980-345479	19800213
	HU 28315	O	19831228	HU 1980-327	19800213
	HU 185011	B	19841128		
	CH 643142	A	19840530	CH 1980-1177	19800213
	FI 8000450	A	19800815	FI 1980-450	19800214
	FI 71483	B	19861010		
	FI 71483	C	19870119		
	US 4218438	B1	19831213	US 1982-90000258	19820917
PRAI	US 1979-12165		19790214		

IT **2063-69-6**
RL: BIOL (Biological study)
(anticoccidial compn. contg. polyether antibiotic and)
RN 2063-69-6 CAPLUS
CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[4-(4-chlorophenoxy)phenyl]-(9CI) (CA INDEX NAME)



L12 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2003 ACS
GI For diagram(s), see printed CA Issue.
AB Eighty-eight (thio)ureas I [X = O or S; R = e.g. H, 2-Cl, 3-CF3, or 4-Me; R1 = e.g. 4-MeO, 4-MeS, 4-CF3S, 4-CCl2HCF2O, 4-ClC6H4O, or 4-[4-(3-CF3SC6H4NHCONH)C6H4SO2]; R2 = e.g. H, 4-Cl, 5-NO2, 5-CF3, or 4-ClCH:CClO; R3 = e.g. H, 4-MeO, or 4-Cl; R4 = e.g. H, 6-CF3, or 5-Cl], used in the treatment of coccidiosis in chicken, were manufd. in 75-90%

yield by reaction of phenyl iso(thio)cyanates with anilines in inert solvents contg. a tertiary org. base 1 hr at reflux temp.

AN 1975:139800 CAPLUS
DN 82:139800
TI Diphenyl(thio)ureas
IN Raether, Wolfgang; Schoenowsky, Hubert; Hoerlein, Gerhard; Winkelmann, Erhard
PA Farbwerke Hoechst A.-G.
SO Ger. Offen., 20 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 2334355	A1	19750116	DE 1973-2334355	19730706
PRAI DE 1973-2334355		19730706		

IT **2063-69-6P**
RL: PREP (Preparation)
(manuf. of coccidiostatic)
RN 2063-69-6 CAPLUS
CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[4-(4-chlorophenoxy)phenyl]-(9CI) (CA INDEX NAME)



L12 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2003 ACS
AB I, II, III, and IV are prepd. and tested against snails such as Helix, Arion, Limax, Deroceras, Planorbis, Bulinus, Biomphalaria, Australorbis glabratus, and their eggs. To 21.3 g. p-ClC6H4CH2NH2 in 100 ml. dioxane 32.2 g. 4,3-Cl(F3C)C6H3NCO in 50 ml. dioxane is added dropwise and after 30 min. 500 ml. water added to give 43 g. I (X = O, R = R1 = R2 = R5 = H, R3 = CF3, R4 = Cl), m. 159-60.5.degree. (EtOH). The tabulated compds. are effective against A. glabratus. A compn. contg. 0.5 g. active compd., 0.5 ml. "Tween 80," and 5 ml. Me2NCHO in Me2CO to 10 ml. is used. Alternatively, Me2SO is used. Also prepd. are m-MeC6H4NH-CSNMeOMe, and 1-naphthyly-3-propylurea, m. 191-2.degree.. Formulations are given for water-xylene emulsions. Quant. measures of effectiveness appear. The compds. prepd. (I-IV) are shown in the tables.
AN 1969:491052 CAPLUS
DN 71:91052
TI Urea and thiourea derivatives useful against molluscs and snails
PA CIBA Ltd.
SO Fr., 9 pp.
CODEN: FRXXAK
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI FR 1511325 19680126
PRAI CH 19660308
IT **23751-88-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 23751-88-4 CAPLUS
CN Carbanilide, 3-chloro-4-phenoxy-3',5'-bis(trifluoromethyl)- (8CI) (CA INDEX NAME)



L12 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2003 ACS
AB The title compds. of the general formula R1NHCONHR (I), where R = substituted or unsubstituted phenyl or phenoxyphenyl, R1 = (F3C)2C6H3 which may or may not be further substituted, have bactericidal and insecticidal properties. To a soln. of 3,4-dichlorophenyl isocyanate 188 in 1 l. MeNO2 is added 3,5-(F3C)2C6H3NH2 229 parts and the mixt. heated 3 hrs. at 80.degree. and cooled to give I (R = 3,4-Cl2C6H3, R1 = 3,5(F3C)2C6H3), m. 210-12.degree. (MeOH). COCl2 is passed into a soln. of 3,5-(F3C)2C6H3NH2 229 in acetone 800, during which time AcONa 190 in H2O 500 parts is added dropwise. When the reaction mixt. becomes weakly acid it is dild. with H2O to ppt. I (R = R1 = 3,5-(F3C)2C6H3), m. 242-3.degree. (MeOH). To 2,4,6-MeO(F3C)2C6H2NH2 259 in PhCl 600 at 60.degree. is added dropwise 3,4-dichlorophenyl isocyanate 188 parts and the reaction mixt. heated 4 hrs. at 60.degree., then cooled to ppt. I (R = 3,4-Cl2C6H3, R1 = 2,4,6-(F3C)2(MeO)C6H2), m. 220-2.degree. (iso-PrOH). 2-Amino-4-methyl-3',4'-dichlorodiphenyl ether 278 in C6H6 1000 is added dropwise to 3,5-bis(trifluoromethyl)phenyl isocyanate 252 in PhCl 2000 parts and the mixt. heated 6 hrs. at 80.degree. and cooled to give II, m. 190-2.degree. (PHCl). Similarly prepd. by one or other of the 4 methods outlined above are the following I (R and m.p. given; in all cases R1 = 3,5-(F3C)2C6H3): 4,3-Cl(F3C)C6H3, 164-6.degree.; 3,5-Cl2C6H3, 212-14.degree.; 3,4,5-Cl3C6H2, 318-21.degree.; 3,4,6-Cl3C6H2, 280-3.degree.; 3,4,6-Cl2(MeO)C6H2, 190-3.degree.; 4,5-EtO(F3C)C6H3, 203-5.degree.; 4,5,2-Cl2(F3C)C6H2, 194-7.degree.; p-O2NC6H4, 289-93.degree.; p-ClC6H4, 212-13.degree.; Ph, 183-4.degree.; 3-m-F3CC6H4, 172-3.degree.; 4,2-Cl(F3C)C6H3, 202-3.degree.; 2,5-Cl(F3C)C6H3, 208-10.degree.; 2,5,4-Cl2(F3C)C6H3, 190-2.degree.; 4,2-Cl(O2N)C6H3, 184-6.degree.; p-PhOC6H4 171-2.degree.; m-PhOC6H4, 176-7.degree.; p-(p-ClC6H4O)C6H4, 181-3.degree.; 5,2-Cl(p-ClC6H4O)C6H3, 196-8.degree.; p-(3,4-Cl2C6H3O)-C6H4, 188-90.degree.; p-(2,4-C6H3O)C6H4, 182-3.degree.; 5,2-Cl(p-MeC6H4O)C6H3, 189-91.degree.; 5,2-(F3C)(p-ClC6H4O)C6H3, 199-200.degree.; 5,2-Cl(p-C5H11C6H4O)C6H3, 190-2.degree.; 5,2-Me(p-ClC6H4O)C6H3, 183-5.degree.; p(C5H11C6H4O)C6H4, 179-80.degree.; p-(tert-BrC6H4O)C6H4, 190-1.degree.; 5,2-Me(p-MeC6H4O)C6H3, 180-2.degree.; 5,2-Me(3,4-Me2C6H3O)C6H3, 178-80.degree.; p-(ClC6H4S)C6H4, 186-8.degree.; p-(MeC6-H4S)C6H4, 182-3.degree.; 2,4-Br2C6H3, 188-90.degree.; 3,4-ClBrC6H3, 217-18.degree.. Also prepd. were the following I (R1 = 4,3,5-Cl(F3C)2C6H2, R and m.p. given): 185-91.degree.; 3,4-Cl2C6H3, 223-5.degree.. Details are given of compns. of these compds. in soaps and

cleansing agents.
AN 1964:82673 CAPLUS
DN 60:82673
OREF 60:14438c-h
TI Diphenylurea derivatives
PA J. R. Geigy A.-G.
SO 10 pp.
DT Patent
LA Unavailable

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 921682		19630320	GB	
US 3230141		1966	US	
PRAI CH		19590814		

IT **1993-38-0**, Carbanilide, 2-(p-chlorophenoxy)-3',5,5'-tris(trifluoromethyl)-
(prepn. of)
RN 1993-38-0 CAPLUS
CN Carbanilide, 2-(p-chlorophenoxy)-3',5,5'-tris(trifluoromethyl)- (7CI, 8CI) (CA INDEX NAME)



=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	133.26	843.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-18.23	-18.23

FILE 'REGISTRY' ENTERED AT 15:52:35 ON 10 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JAN 2003 HIGHEST RN 478613-03-5
DICTIONARY FILE UPDATES: 9 JAN 2003 HIGHEST RN 478613-03-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002